Navigation Links
Hoosier Oncology Group Selects OnCore to Support Clinical Trials Network
Date:8/7/2013

MADISON, Wis. and INDIANAPOLIS, Aug. 7, 2013 /PRNewswire/ -- Forte Research Systems, developer of specialized clinical research software, and the Hoosier Oncology Group ("the HOG"), a leading not-for-profit company specializing in the management of investigator-initiated clinical trials, are pleased to announce that HOG has selected Forte's OnCore® Enterprise Research system to support the trials of the newly formed Big Ten Cancer Research Consortium, as well as the HOG's additional portfolio of clinical trials.

(Logo: http://photos.prnewswire.com/prnh/20101115/CG02078LOGO)

The HOG will use functionality within OnCore to streamline the administration of trials, including financials management and electronic data capture, across its network.

Collaboration in Oncology Clinical Trials
The HOG supports more than 400 research center physicians and practitioners throughout its network. It is also the administrative headquarters of the Big Ten Cancer Research Consortium, a network consisting of 12 academic cancer centers and research universities that have come together to collaborate and conduct highly translational oncology trials.

Officially launched in June, the new consortium leverages its members' collective expertise and streamlines the process of conducting trials. Through their combined efforts, the centers have access to more than 30,000 new patients each year.  

"The Big Ten Cancer Research Consortium is a new collaborative endeavor that has been created to transform the way oncology trials are conducted," said Tim Breen, Data Systems Director at the HOG. "It was important to select the right system to accomplish these goals, and we decided that the OnCore system was the best solution."

Srini Kalluri, Founder, CEO, and Chief Customer Officer at Forte, believes the selection of OnCore to support the consortium represents an opportunity to enhance existing relationships with institutions while building new ones. "We are pleased to have already been working with more than half of the institutions in the Big Ten Cancer Research Consortium, and we are excited to expand our support to the other institutions involved," he said. "The collaboration is an exciting new endeavor in clinical research, and we are thrilled to be a part of it."  

About Forte Research Systems, Inc.
Founded in 2000 and headquartered in Madison, Wisconsin, Forte Research Systems, Inc. develops and markets clinical and translational research software for better research compliance, patient safety, operational efficiency, and financial viability. The company's flagship product, the OnCore® Enterprise Research solution, has been meeting the needs of academic medical centers, CTSAs, research hospitals, and cancer centers for over a dozen years. Now, its proven electronic data capture platform is available as a stand-alone hosted solution for academic researchers, Overture™ EDC. For Research Sites, Site Networks, and SMOs, Forte offers Allegro® CTMS. Forte is also host to the Clinical Research Blog and other resources for individuals interested in excellence in clinical research operations.

About Hoosier Oncology Group
The Hoosier Oncology Group, Inc. (affectionately nicknamed "the HOG") consists of a working association of over 400 dedicated community and research center physicians and clinical research practitioners. The HOG is committed to improving therapy for cancer patients through clinical research throughout its network.


'/>"/>
SOURCE Forte Research Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orfit Launches Open Face Hybrid Mask For Patient Immobilization In Radiation Oncology
2. Life Technologies and RainTree Oncology Services Announce Collaboration to Bring Molecular Tumor Testing to Community Oncologists
3. Astellas Appoints New Senior Vice President of Global Oncology Development
4. Oncology remains most restrictive specialty for second year
5. Using Success & Failure Roadmap Paves the Way for Positive New Product Launches in Oncology
6. Accelovance Primed to Achieve Leadership in Oncology Clinical Trials
7. Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
8. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
9. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
10. PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
11. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... Texas , Dec. 8, 2016 ... program that brings leading-edge laboratory services and management ... United States , allowing more doctors and ... health care management solutions. Logo - ... Hospital systems, under pressure to contain ...
(Date:12/8/2016)... Information products and services provider Elsevier has ... the world,s largest abstract and citation database of peer-reviewed literature, providing ... over 5,000 publishers. The new set of metrics will improve decisions ... to adjust a journal,s editorial strategy. ... , , CiteScore metrics ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that ... for Texas, they are expanding their presence in Dallas. One of the most exciting ... bring new jobs to the Dallas and Forth Worth market. STAT takes pride in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):